A universal vaccine for serogroup B meningococcus.
Meningitis and sepsis caused by serogroup B meningococcus are two severe diseases that still cause significant mortality. To date there is no universal vaccine that prevents these diseases. In this work, five antigens discovered by reverse vaccinology were expressed in a form suitable for large-scale manufacturing and formulated with adjuvants suitable for human use. The vaccine adjuvanted by aluminum hydroxide induced bactericidal antibodies in mice against 78% of a panel of 85 meningococcal strains representative of the global population diversity. The strain coverage could be increased to 90% and above by the addition of CpG oligonucleotides or by using MF59 as adjuvant. The vaccine has the potential to conquer one of the most devastating diseases of childhood.
Giuliani
Marzia M
MM
Novartis Vaccines, Via Fiorentina 1, 53100 Siena, Italy.
Adu-Bobie
Jeannette
J
Comanducci
Maurizio
M
Aricò
Beatrice
B
Savino
Silvana
S
Santini
Laura
L
Brunelli
Brunella
B
Bambini
Stefania
S
Biolchi
Alessia
A
Capecchi
Barbara
B
Cartocci
Elena
E
Ciucchi
Laura
L
Di Marcello
Federica
F
Ferlicca
Francesca
F
Galli
Barbara
B
Luzzi
Enrico
E
Masignani
Vega
V
Serruto
Davide
D
Veggi
Daniele
D
Contorni
Mario
M
Morandi
Maurizio
M
Bartalesi
Alessandro
A
Cinotti
Vanda
V
Mannucci
Donatella
D
Titta
Francesca
F
Ovidi
Elisa
E
Welsch
Jo Anne
JA
Granoff
Dan
D
Rappuoli
Rino
R
Pizza
Mariagrazia
M
D000818:Animals; D000906:Antibodies / Q000276:immunology; D000942:Antigens, Bacterial / Q000276:immunology; D004195:Disease Models, Animal; D006801:Humans; D008585:Meningitis, Meningococcal / Q000276:immunology / Q000382:microbiology / Q000517:prevention & control; D022401:Meningococcal Vaccines / Q000276:immunology*; D051379:Mice; D046529:Microscopy, Electron, Transmission; D038541:Neisseria meningitidis, Serogroup B / Q000145:classification / Q000276:immunology* / Q000648:ultrastructure; D051381:Rats
D000906:Antibodies; D000942:Antigens, Bacterial; D022401:Meningococcal Vaccines